Latest Breaking News On - Christian rommel - Page 8 : comparemela.com

New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anti

New study includes patients aged ≥65 years with atrial fibrillation (AF) at high risk for ischemic stroke or systemic embolism who are deemed ineligible for oral anticoagulant (OAC) treatment due to increased risk of bleedingOCEANIC-AFINA, the latest Phase III study in the OCEANIC clinical trial program, will invest.

United statesRoxana mehranChristian rommelXia fxiaBayer agHaass internationalJournal of the american heart associationInterventional cardiovascular researchGlobal head of researchInternational society on thrombosisDrug administrationExecutive committeeGlobal headClinical trialsIcahn schoolInternational society

New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with

FIGARO-BM, an exploratory human biomarker study, provides additional insight on finerenone's mechanism of action in blocking mineralocorticoid receptor (MR) overactivation1New data presented at the American Society of Nephrology’s (ASN) Kidney Week 2023WHIPPANY, N.J. (BUSINESS WIRE) At the American Society of Neph.

United statesSemin nephrolChristian rommelAmerican society of nephrologyClinical trials programCenters for diseaseNational diabetes statisticsAmerican kidney fundBayer healthcare pharmaceuticals incNational institutes of healthHead of researchAmerican diabetes associationNational institute of diabetesAmerican association of clinical endocrinologyAmerican societyKidney week

New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

WHIPPANY, N.J. (BUSINESS WIRE) Nov 2, 2023

United statesSemin nephrolChristian rommelAmerican kidney fundNational diabetes statisticsHead of researchNational institute of diabetesAmerican diabetes associationBayer healthcare pharmaceuticals incNational institutes of healthClinical trials programAmerican society of nephrologyAmerican association of clinical endocrinologyCenters for diseaseAmerican societyKidney week

Bayer and BlueRock announce positive results from Parkinson s cell therapy trial

Bayer and BlueRock announce positive results from Parkinson s cell therapy trial
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United kingdomChristian rommelAhmed enayetallahInternational congressMovement disordersBluerock therapeutics

Bayer says Parkinson s stem cell therapy improves symptoms in initial trial

Bayer said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson s disease symptoms in an early 12-patient trial. The German.

United statesUnited kingdomSusan fentonLudwig burgerChristian rommelHarvard universityBritain cambridge universityInternational stem cell corp cyto therapeuticsInternational congressJapan kyoto university hospitalChinese academy of sciencesMovement disordersCambridge universitySouth koreaInternational stem cell corpCyto therapeutics